Afficher la notice abrégée

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHALOUNI, Mathieu
dc.contributor.authorSOGNI, P.
dc.contributor.authorMIAILHES, P.
dc.contributor.authorLACOMBE, K.
dc.contributor.authorPOIZOT-MARTIN, I.
dc.contributor.authorCHAS, J.
dc.contributor.authorVITTECOQ, D.
dc.contributor.authorNEAU, D.
dc.contributor.authorAUMAITRE, H.
dc.contributor.authorALRIC, L.
dc.contributor.authorPIROTH, L.
dc.contributor.authorBOUCHAUD, O.
dc.contributor.authorKATLAMA, C.
dc.contributor.authorMORLAT, P.
dc.contributor.authorLASCOUX-COMBE, C.
dc.contributor.authorGERVAIS, A.
dc.contributor.authorNAQVI, A.
dc.contributor.authorROSENTHAL, E.
dc.contributor.authorGARIPUY, D.
dc.contributor.authorBARANGE, K.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorESTERLE, Laure
dc.contributor.authorSALMON, D.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.date.accessioned2020-06-04T09:03:55Z
dc.date.available2020-06-04T09:03:55Z
dc.date.issued2019
dc.identifier.issn1473-5687 (Electronic) 0954-691X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7742
dc.description.abstractEnOBJECTIVES: HIV/hepatitis C virus (HCV) co-infection leads to major complications, and noninvasive markers developed to stage liver fibrosis could be used as prognostic markers. We aimed to compare the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to predict liver-related events in HIV/HCV co-infected patients. PATIENTS AND METHODS: HIV/HCV co-infected patients from the ANRS CO13 HEPAVIH cohort were included if they had LS, FIB-4, and APRI measurements done in a window of 3 months. Primary outcome was the time between inclusion and occurrence of a liver-related event. Univariable and multivariable Fine and Gray models were performed. Predictive performances were compared by the area under the receiver operating characteristic (AUROC) differences after correction of optimistic by bootstrap samples. Best cutoffs to predict liver-related events were estimated by sensitivity and specificity maximization. RESULTS: A total of 998 patients were included. Overall, 70.7% were men. Their median age was 46.8 years. According to LS value, 204 (20.4%) patients had cirrhosis. Overall, 39 patients experienced at least one liver-related event. In univariable analysis, LS AUROC curve was significantly superior to FIB-4 and APRI AUROC curves, being 87.9, 78.2, and 75.0%, respectively. After adjustment on age, CD4 levels, and insulin resistance, no differences were observed. The best cutoffs to identify patients at low or high risk of liver-related events were below 8.5, 1.00, and 0.35 and above 16.5, 4.00, and 1.75 for LS, FIB-4, and APRI, respectively. CONCLUSION: To predict HCV-related events, APRI had lower performance than LS and FIB-4. FIB-4 is as good as LS to predict HCV-related events, suggesting that it can be used for the management of HIV/HCV co-infected patients and replace LS.
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.subject.enANRS CO13 HEPAVIH
dc.title.enLiver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort
dc.title.alternativeEur J Gastroenterol Hepatolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/meg.0000000000001408en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31033848en_US
bordeaux.journalEuropean journal of gastroenterology & hepatologyen_US
bordeaux.page1387-1396en_US
bordeaux.volume31en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.date=2019&rft.volume=31&rft.issue=11&rft.spage=1387-1396&rft.epage=1387-1396&rft.eissn=1473-5687%20(Electronic)%200954-691X%20(Linking)&rft.issn=1473-5687%20(Electronic)%200954-691X%20(Linking)&rft.au=CHALOUNI,%20Mathieu&SOGNI,%20P.&MIAILHES,%20P.&LACOMBE,%20K.&POIZOT-MARTIN,%20I.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée